



July - September 2026

Inpharmus Quarterly Brief:

Connecting scientific collaboration with regional impact

The third quarter of 2026 brought together scientific exchange, regional collaboration, organizational development, and important conversations about the future of healthcare.

Across Türkiye, Saudi Arabia, Kuwait, Europe, and the United States, Inpharmus continued to engage with healthcare professionals, scientific communities, partners, and industry stakeholders, strengthening the connection between global scientific progress, regional expertise, and patient needs.

Scientific Engagement: Oncology

In July, scientific meetings across Saudi Arabia brought experts together to exchange perspectives on advances in Neuroblastoma research and pediatric oncology awareness.



Scientific Collaboration: Supporting Pediatric Care

The Treat & Protect initiative continued during Q3, building on the scientific discussions developed throughout the first half of the year.

In July, Inpharmus brought together experts in Pediatric Oncology and Rare Diseases for the first Treat & Protect Summit in Saudi Arabia.

The summit emphasized an important principle at the heart of the initiative: supporting long-term well-being and quality of life throughout the patient journey.

The meeting provided a platform for scientific exchange and collaboration, reinforcing the importance of bringing different perspectives together to support children and their families.



Leadership & Organizational Development

In July, Mehmet Beyazyürek continued his journey at Inpharmus in the role of Regional Operations Director, supporting the company's growing regional operational structure.

On July 31, Inpharmus Head Office teams came together with the CEO and Regional Operations Director in Istanbul for the G&A Mid-Year Meeting. The meeting provided an opportunity to review the first half of 2026 and align on priorities for the months ahead.



Media & Healthcare Perspectives

In August, Inpharmus Türkiye General Manager Batuhan Özenç spoke to Capital about Türkiye’s potential to become a regional hub for innovative therapies, highlighting the importance of scientific expertise, access models, local capabilities, and future investment opportunities.

The same month, Inpharmus Türkiye Medical Director Mehmet Emin Apaydın shared his perspective with PharmaWorld on the evolving role of Medical Affairs, with a focus on scientific communication, patient-centricity, and collaboration with healthcare professionals.

PharmaWorld Interview: <https://pharmaworlddergi.com/inpharmus-medikal-ekibi-hasta-yasamina-deger-katmaya-odaklaniyor/>



Rare Diseases: Scientific Exchange & Awareness

During SSIEM, representatives from Inpharmus and Immedica Pharma also came together to discuss potential collaborations and follow-up activities related to a rare metabolic disease, while exchanging perspectives on the needs of young patients.



Leadership & Organizational Development

In August, Assoc. Prof. Tolga Tunçel rejoined Inpharmus as Regional Scientific Director. Based in Dubai, he will contribute to the development of regional scientific strategies, the strengthening of the medical organization, and international scientific collaboration.



Media & Healthcare Perspectives

September brought further perspectives. Inpharmus Türkiye General Manager Batuhan Özenç discussed transformation, collaboration, and regional leadership in Ekonomist, while Executive Board Member and Strategic Stakeholder Relations Director Tansu Demirkale addressed the changing landscape of market access and sustainable access to innovative therapies in Workshop.

Regional Scientific Director Assoc. Prof. Tolga Tunçel also joined EkoTürk’s Akşam Masası on FMF Awareness Day to discuss Familial Mediterranean Fever, disease awareness, and the diagnostic journey.

EkoTürk Interview: <https://www.youtube.com/watch?v=7P6eB-21XFQ>



Scientific Engagement: Oncology

In September, Inpharmus participated in the 3rd Kuwait Pediatric Oncology Conference & 1st GCC Pediatric Oncology Conference, bringing together global and regional expertise in pediatric oncology. Prof. Shakeel Modak joined as an international speaker, contributing scientific insights into the management of High-Risk Neuroblastoma.

Later in the month, Inpharmus joined the international pediatric oncology community at SIOP 2026 in San Antonio, providing another opportunity to follow scientific developments, exchange perspectives, and bring new insights back to our teams.

Together, these activities reflected our continued commitment to scientific exchange and collaboration across the pediatric oncology community.



Rare Diseases: Scientific Exchange & Awareness

In September, Inpharmus participated in the 3rd Masterclass on Inborn Errors of Immunity (IEI), joining leading immunologists from across the region to exchange scientific insights, strengthen partnerships, and discuss unmet needs in rare immunological diseases.

FMF Awareness Day on September 17 provided another opportunity to support greater understanding of Familial Mediterranean Fever, highlighting disease recognition, diagnosis, and appropriate follow-up.

Across these activities, scientific exchange and disease awareness remained closely connected to a shared objective: supporting better recognition, understanding, and care in rare diseases.

FMF Awareness Day video: <https://www.youtube.com/watch?v=2YbH74LkAfw&t=35s>



Leadership & Organizational Development

From September 2–4, Inpharmus Türkiye Marketing and Medical Teams gathered in TRNC for a three-day field cycle meeting, training, and workshop programme. The teams reviewed the first half of 2026, aligned on priorities for the remainder of the year, and began planning for 2027.

Together, these developments reflected the importance of strong leadership, internal alignment, and cross-functional collaboration in supporting Inpharmus’ regional growth.



Looking Ahead

Across three months of scientific meetings, regional collaborations, leadership developments, awareness initiatives, and healthcare discussions, one theme remained consistent:

How can scientific progress and regional expertise work together to create meaningful impact for patients and healthcare systems?

As we move into the final quarter of 2026, Inpharmus will continue strengthening connections between science, healthcare professionals, partners, and regional needs, supporting our role as a trusted bridge between global innovation and the MERAT healthcare ecosystem.